Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04169711 · ClinicalTrials.gov registry record · Phase 1

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Arrowhead Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
5
Study locations

NCT04169711 is a Phase 1 study of Clear Cell Renal Cell Carcinoma that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 26 participants, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04169711, a Phase 1 study of Clear Cell Renal Cell Carcinoma, has completed, sponsored by Arrowhead Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

Conditions Studied

Clear Cell Renal Cell Carcinoma

Interventions

  • DRUG ARO-HIF2

Study Locations (5)

Texas

  • Research Site 5 - Dallas
  • Research Site 6 - Houston

Colorado

  • Research Site 1 - Aurora

Nevada

  • Research Site 2 - Las Vegas

Tennessee

  • Research Site 4 - Nashville

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2020-08-17
Est. Completion 2022-07-22
Phase Phase 1

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04169711

The ClinicalTrials.gov registry entry for NCT04169711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ARO-HIF2 is the first listed.

NCT04169711 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Colorado, Nevada.

Frequently Asked Questions

What is clinical trial NCT04169711 about?

NCT04169711 is a clinical study titled "Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma". The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

What is the current status of trial NCT04169711?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-08-17. Estimated completion is 2022-07-22.

What conditions does trial NCT04169711 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.

What interventions are being tested in trial NCT04169711?

The interventions under investigation include: ARO-HIF2 (DRUG).

Who is sponsoring clinical trial NCT04169711?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04169711 being conducted?

This trial has 5 study locations across Colorado, Nevada, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.